A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

This study has been completed.
Sponsor:
Information provided by:
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT00106431
First received: March 24, 2005
Last updated: March 14, 2011
Last verified: March 2011
  Purpose

GPI-04-0001 was a Phase II, non-randomized, open label, single arm study that was conducted at approximately 30 sites, primarily in the United States, Europe and Russia. It assessed the efficacy, safety, and tolerability of romidepsin as a treatment for cutaneous T-cell lymphoma (CTCL). Study patients (pts) received romidepsin in a dose of 14 mg/m^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although pts who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.


Condition Intervention Phase
Cutaneous T-cell Lymphoma
Drug: romidepsin (depsipeptide, FK228)
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma

Resource links provided by NLM:


Further study details as provided by Celgene Corporation:

Primary Outcome Measures:
  • The Percent of Patients (Pts) With Objective Disease Response [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The percent of pts with confirmed Objective Disease Response (confirmed best responses of complete response [CR], clinical complete response [CCR], or partial response [PR]). Responses were evaluated according to a composite assessment (Objective Primary Disease Response Evaluation Criteria - OPDREC).


Secondary Outcome Measures:
  • Duration of Objective Disease Response [ Time Frame: Up to 10 months; median duration of follow up was 5.1 months ] [ Designated as safety issue: No ]
    Duration of Objective Response was defined as the number of months from the date of the first disease response (clinical complete response [CCR], or partial response [PR]) (later confirmed) until the date of progression and was determined using Kaplan-Meier product-limit estimates. In this analysis, pts who did not progress were censored as of their last evaluation with an OPDREC assessment.

  • Time to Objective Disease Response [ Time Frame: Up to 10 months ] [ Designated as safety issue: No ]
    Time to Objective Response was defined as the time in months from first dose date to the first date of objective disease response (later confirmed) and time to CCR was defined as the time in months from first dose date to the first date of CCR (later confirmed).

  • Time to Disease Progression [ Time Frame: Up to 10 months; median duration of follow up was 6.1 months ] [ Designated as safety issue: No ]
    Time To Progression was defined as the duration from the date of the first study drug dose to the date of progression (PD). In this analysis, pts who did not progress were censored at their last evaluation with an OPDREC assessment.

  • Decrease in Pruritus Visual Analogue Scale (VAS) Score of ≥30 mm or a Score of 0 for at Least 2 Consecutive Cycles. [ Time Frame: Up to 10 months ] [ Designated as safety issue: No ]
    Pruritus was reported monthly by pts using a 0 (no itching) to 100 (unbearable itching) mm visual analog scale (VAS). Pts were considered to have significant pruritus if the baseline VAS score was ≥ 30 mm. Clinically meaningful reduction in pruritus was defined as a decrease in VAS score of ≥ 30 mm or a score of 0 for at least 2 consecutive cycles.

  • Duration of Objective Disease Control (ODC) [ Time Frame: Up to 10 months; median duration of follow up was 6.0 months ] [ Designated as safety issue: No ]
    For pts with confirmed ODC (pts with CR, CCR, PR, SD90 [stable disease for 90 days]) based on OPDREC, duration of ODC was summarized with descriptive statistics, including number of censored observations, and 25th, 50th, 75th percentiles of distribution, based on Kaplan-Meier product limit estimates. For pts with confirmed progressive disease (PD), duration of ODC was calculated from first date of study drug to first date of diagnosis of confirmed PD. For pts without confirmed PD, duration of ODC was calculated from first date of study drug to date of the last visit with any OPDREC data.

  • Percent of Pts With Objective Disease Control [ Time Frame: Up to 10 months ] [ Designated as safety issue: No ]
    The percent of pts with confirmed ODC (CR, CCR, PR and SD90) based on OPDREC was summarized.


Enrollment: 102
Study Start Date: January 2005
Study Completion Date: December 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: romidepsin (depsipeptide, FK228)
    Study patients received romidepsin at a dose of 14 mg/m^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
Detailed Description:

Responses were evaluated according to a composite assessment (Objective Primary Disease Response Evaluation Criteria [OPDREC]) that included cutaneous manifestations of disease, lymph node involvement, and circulating malignant T-cells (Sézary cells). Skin involvement was measured using a weighted body surface area skin assessment tool (WBSA/SWAT) or an erythroderma score, depending upon the pt's disease. Disease response was assessed by the Investigators and an Independent Response Review Committee (IRRC) with the IRRC assessment considered supportive of the Investigator's evaluations using the following criteria:

Complete Response (CR):

  • Complete resolution of skin patches, skin plaques, and skin tumors, or erythroderma
  • No evidence of abnormal lymph nodes
  • Absence of circulating Sézary cells.
  • No evidence of new tumors (cutaneous or non-cutaneous)
  • Findings confirmed by skin biopsy

Clinical complete response (CCR):

- Same as CR but without skin biopsy

Partial Response (PR):

  • ≥50% improvement in the summation of (change in Skin + change in Lymph Node + change in Peripheral Blood) with
  • At least >30% improvement in Skin and
  • No worsening in Lymph Node or Sézary cells.
  • No evidence of new tumors (cutaneous/non-cutaneous)

Stable Disease (SD):

  • Not enough improvement or worsening in the summation of (change in Skin + change in Lymph Node + change in Peripheral Blood to qualify as PR or PD
  • No evidence of new tumors (cutaneous/non-cutaneous)

SD90:

- SD90 was defined as documented evidence of SD for at least 90 Days Duration

Progressive Disease (PD):

  • Evidence of new tumor (cutaneous or non-cutaneous), OR
  • >25% worsening in the summation of (change in Skin + change in Lymph Node + change in Peripheral Blood) with >15% worsening in change in Skin.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: Patients had to fulfill all of the following criteria to be eligible for study participation:

  • Males or non-pregnant females aged 18 or over.
  • Histologically confirmed diagnosis of CTCL, including mycosis fungoides and Sézary syndrome.
  • Patients with CTCL stages II-A, II-B, III, and IV-A only.
  • Patients with CTCL stage IB who had relapsed following previous therapy and where, in the investigator's opinion, the potential benefit of treatment with romidepsin outweighed the possible risks.
  • Patients who had failed standardized skin-directed therapy and had had at least one course of systemic therapy, such as interferon, Ontak®, chemotherapy or Targretin®, etc., which they were deemed to have failed.
  • Anticipated life expectancy greater than six months.
  • Written informed consent to participate in the study.

Exclusion Criteria: Patients were ineligible for entry if any of the following criteria were met:

  • ECOG Performance Status >1.
  • Patients who had not received at least 1 course of prior systemic therapy for CTCL.
  • Visceral involvement i.e. Stage 4B disease (lymphadenopathy was allowed).
  • Patients with known cardiac abnormalities such as:

    • Congenital long QT syndrome
    • QTc (Corrected QT interval on ECG) interval >480 milliseconds
    • Any cardiac arrhythmia requiring anti-arrhythmic medication.
  • Patients who had had a myocardial infarction within 12 months of study entry.
  • Patients who had a history of coronary artery disease (CAD) e.g. angina Canadian class II to IV. In any patient in whom there was doubt, the patient should have had a stress imaging study and exercise electrocardiogram (ECG) and, if abnormal, angiography to define whether or not CAD was present.
  • Patients with an ECG recorded at screening showing evidence of cardiac ischaemia (ST depression of >=2 mm). If in any doubt, the patient should have had a stress imaging study and exercise ECG and, if abnormal, angiography to define whether or not CAD is present.
  • Patients with congestive heart failure that met New York Heart Association class II to IV definitions and/or ejection fraction <40% by multiple gated acquisition (MUGA) scan or <50% by echocardiogram and/or magnetic resonance imaging (MRI)
  • Patients with a history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest, unless currently addressed with an automatic implantable cardioverter defibrillator (AICD).
  • Patients with hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes (if in doubt, see ejection fraction criteria above).
  • Patients with uncontrolled hypertension, i.e. >=160/95 mmHg.
  • Concomitant use of any anti-cancer therapy.
  • Concomitant use of warfarin (due to a drug interaction).
  • Concomitant use of any investigational agent.
  • Use of any investigational agent within 4 weeks of study entry.
  • Concomitant use of drugs which may cause a prolongation of the QTc interval.
  • Patients with a potassium level of <3.5 mmol/L and a magnesium level of <0.8 mmol/L.
  • Clinically significant active infection.
  • Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
  • Inadequate bone marrow or other organ function, as evidenced by:

    • unsupported haemoglobin <9.0 g/dL (transfusions and/or erythropoietin were permitted);
    • absolute neutrophil count (ANC) <=1.5 x 10^9/L;
    • platelet count <100 x 10^9/L;
    • total bilirubin >1.25 x upper limit of normal (ULN) for institution,
    • aspartate transaminase/glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/ glutamic pyruvic transaminase (ALT/SGPT) >2.0 x ULN, serum creatinine >2.0 x ULN for age and sex;
  • Coexistent second malignancy or history of prior malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin or cervical epithelial neoplasm [CIN1, carcinoma in situ] that had been treated curatively).
  • Any significant medical or psychiatric condition that might have prevented the patient from complying with all study procedures.
  • Patients who were pregnant or breast-feeding. All women of child bearing potential were to use an effective method of contraception (either an intrauterine device or a double barrier method using condoms or a diaphragm plus spermicide) during the study and for at least one month after receiving the last dose of romidepsin. Male patients were to use a barrier method of contraception (condoms) during the treatment period and for at least 1 month thereafter. Hormonal methods of contraception such as the contraceptive pill or patch (particularly those containing ethinyl estradiol) were to be avoided due to a potential drug interaction.
  • Use of topical steroids in the previous 2 weeks or systemic steroids in the previous 4 weeks.
  • Having previously given consent to participate in this study.
  • Concomitant use of CYP3A4 inhibitors.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00106431

Locations
United States, California
UCLA Jonsson Cancer Center
Los Angeles, California, United States, 90095
Stanford Comprehensive Cancer Center
Stanford, California, United States, 94305
United States, Massachusetts
Boston Medical Center
Boston, Massachusetts, United States, 02118
United States, Pennsylvania
University of Pennsylvania Abrahamson Cancer Center
Philadelphia, Pennsylvania, United States, 19104
United States, Tennessee
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
France
Research Site
Various Cities, France
Germany
Research Site
Various Cities, Germany
Poland
Research Site
Various Cities, Poland
Russian Federation
Research Site
Various Cities, Russian Federation
United Kingdom
Research Site
Various Cities, United Kingdom
Sponsors and Collaborators
Celgene Corporation
Investigators
Study Director: Jean Nichols, Ph.D. Gloucester Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Jean Nichols, Ph.D., Gloucester Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT00106431     History of Changes
Obsolete Identifiers: NCT00337025
Other Study ID Numbers: GPI-04-0001
Study First Received: March 24, 2005
Results First Received: March 2, 2010
Last Updated: March 14, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Celgene Corporation:
romidepsin

Additional relevant MeSH terms:
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Romidepsin
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 19, 2014